

<http://www.pjbs.org>

PJBS

ISSN 1028-8880

**Pakistan
Journal of Biological Sciences**

ANSI*net*

Asian Network for Scientific Information
308 Lasani Town, Sargodha Road, Faisalabad - Pakistan

***In vitro* Antimicrobial Screening of Three Cadmium Coordination Complexes and Two Addition Compounds of Antimony and Arsenic**

Chand Sultana, M. Aziz Abdur Rahman, M.A.A. Al-Bari, M.L.A. Banu,
M. Saidul Islam, N. A. Khatune and Golam Sadik

Department of Chemistry, Department of Pharmacy, University of Rajshahi, Rajshahi-6205, Bangladesh

Abstract: Three cadmium coordination complexes (cadmium deprotonated phthalyl pyridine [Cd(DPH)(Py)₂, C₁], cadmium deprotonated phthalyl 8-hydroxy quinoline [Cd(DPH)-8-HQ, C₂] & cadmium deprotonated phthalyl isoquinoline [Cd(DPH)IQ, C₃] and two addition compounds 1:1 antimony(III) chloride with acetophenone [SbCl₃.C₆H₅COCH₃, C₄] & 1:1 arsenic(III)bromide with benzamide [AsBr₃.C₆H₅CONH₂, C₅] were tested for their antimicrobial activity by disc diffusion and serial dilution methods. All the compounds were active against various test pathogenic organisms. The maximum antibacterial and antifungal activities were shown by the compound C₄. The minimum inhibitory concentration (MIC) of the compound C₄ was determined against two Gram positive (*Bacillus subtilis* and *Streptococcus β-haemolyticus*) and two Gram negative (*Shigella dysenteriae*, *Salmonella typhi*) bacteria and the values were found between 4 and 16 μg ml⁻¹.

Key words: Coordination complexes, antimicrobial activity, antifungal activity, pathogens

Introduction

The frequency of life threatening infections such as tuberculosis, cancer, AIDS etc caused by pathogenic microorganisms is increasing worldwide and becoming an important cause of morbidity and mortality in immunocompromised patients. Synthetic compounds constitute an important source of various bioactive compounds such as antibacterial (Zakaria, 2000; Biswas *et al.*, 2002) antifungal and anticancer (Pratt, 1979) compounds. The synthesized compounds which are used for the treatment of infectious diseases are known as chemotherapeutic agents. Every year thousands of compounds are synthesized with an aim to find a potential chemotherapeutic agent to combat pathogenic microorganisms. But very few compounds are withstood as therapeutic agent for various methodological tests. Antimicrobial screening is one of these tests required to perform for primary selection of compounds as the therapeutic agents.

The antimicrobial screening is necessary to find out the suitable candidate of therapeutic agent among the synthesized compounds. Usually many compounds possess antimicrobial properties but have serious toxic effects to the host, therefore in the ideal cases, the drug should be highly toxic to the parasite and completely atoxic for the host. In the continuation of our ongoing efforts aimed to find new compounds for chemotherapy (Islam *et al.*, 2001; Biswas *et al.*, 2002), five new synthesized compounds are selected for antimicrobial screening.

Materials and Methods


Source of Compounds: The compounds used in the

present study were synthesized according to the following general procedure:

Preparation of cadmium coordination complexes [Cd(DPH)(LG*)_x]

An ethanolic solution of cadmium (II) chloride (1.833g; 1.0 mmol) and deprotonated Phthalic acid (DPH, 1.661g; 1.0 mmol) were mixed in the 1:1 ratio with constant stirring. Then an ethanolic ligand solution [LG*]_x (a variable ligand) was added to the resulting mixture and heated gently on a magnetic regulator hot plate with constant stirring. As a result the volume of the solution was reduced to one half and then allowed to cool. The precipitates formed were filtered, washed several times with ethanol and then dried in a vacuum desiccators charged with anhydrous CaCl₂.

When




the compound is [Cd(DPH)(Py)₂, C₁],

when



the compound is [Cd(DPH)(8-HQ), C₂] and

when



the compound is [Cd(DPH)(IQ), C₃].

Preparation of addition compound 1:1 antimony (III) chloride with acetophenone [SbCl₃.C₆H₅COCH₃, C₄] A solution of acetophenone (1.201g, 1.0 mmol) in absolute alcohol was added drop wise with gently stirring to an ethanolic solution of antimony (III) chloride (2.281g, 1.0 mmol) in warm condition. The resulting mixture

was refluxed for seven hours and allowed to cool. Then the volume of this solution was reduced to one half by heating on a hot plate and cooled in a freeze for two days. The precipitate obtained was filtered, washed with ethanol and dried in a vacuum desiccator charged with CaCl_2 .

Preparation of addition compound 1:1 Arsenic (III) bromide with benzamide, $[\text{AsBr}_3, \text{C}_6\text{H}_5\text{CONH}_2, \text{C}_5]$
The benzamide solution (1.21 g, 1.0 mmol) in absolute alcohol was mixed drop wise with gently stirring to an alcoholic solution of arsenic (III) bromide (3.14g, 1.0 mmol) in warm condition. The resulting mixture was refluxed for seven hours and allowed to cool. Then the volume of this solution was reduced one half by heating on a hot plate and cooled in a freeze for two days. The precipitate obtained was filtered, washed with absolute alcohol and dried in a vacuum desiccator charged with CaCl_2 .

Antimicrobial screening: "Disc diffusion method" (Bauer *et al.*, 1966; Barry, 1980; Rios *et al.*, 1988), is a widely accepted procedure for the *in-vitro* investigation of the susceptibility of microorganisms to the compounds, so this method is adopted in this investigation. The method is essentially a qualitative or semiquantitative test indicating sensitivity or resistance of microorganisms to the test materials as well as bacteriostatic or bactericidal activity of a compound (Reiner, 1982).

The standard test microorganisms were collected from the Department of Microbiology, University of Dhaka and ICDDR'B, Dhaka, Bangladesh. The diameters of zones of inhibition produced by the compounds were compared with standard antibiotics (Kanamycin $30 \mu\text{g disc}^{-1}$ and Nystatin $200 \mu\text{g disc}^{-1}$). The experiment was performed in duplicate to minimize errors.

Minimum inhibitory concentration (MIC) of a compound is defined as the lowest concentration of that compound in a medium without visible growth of the test organisms. The basic principle is the dilution tests which comprises the serial dilution of the antimicrobial agent inoculated with the organism. For the test, standard serial dilution technique (Reiner 1982) was employed. The media used in this respect were nutrient agar & nutrient broth (DIFCO).

Results & Discussion

Antibacterial activity: The inhibitory activity of the compounds C_1 , C_2 , C_3 , C_4 & C_5 was determined at a concentration of $100 \mu\text{g/disc}$ against a series of Gram positive and Gram negative pathogenic bacteria. The results are shown in Table 1. Results revealed that all the tested compounds have strong activity against most of the Gram positive & Gram negative bacteria. Among the tested materials, the compound C_4 (i.e. $\text{SbCl}_3, \text{C}_6\text{H}_5\text{COCH}_3$) was found to be most active than others. When compared with standard antibiotic Kanamycin at the same

concentration of $30 \mu\text{g disc}^{-1}$, the compound C_4 also has shown substantial antimicrobial activity.

In Table 1, the antibacterial activity of the three synthetic cadmium coordination complexes against 14 pathogenic bacteria is presented. Among these three complexes the antibacterial activity of compound C_2 is greater than compound C_1 and compound C_3 . So the structural activity correlation with antibacterial screening data reveal that the cadmium complexation with the ligand 8- hydroxy quinoline rather than pyridine and isoquinoline is necessary for greater antibacterial activity (activity of the compounds can be represented sequentially, $\text{C}_2 > \text{C}_1 > \text{C}_3$). On the other hand, among the two addition compounds C_4 and C_5 , the antibacterial activity is approximately same in both compounds but in case of compound C_5 , the antibacterial activity against *Sarcina lutea* and *Shigella dysenteriae* is so much lower than the compound C_4 . So we can select the compound C_4 for further tests such as subacute toxicity as for suitable therapeutic antibacterial agent.

Antifungal activity: The compounds C_1 , C_2 , C_3 , C_4 & C_5 were tested against the pathogenic fungi at a concentration of $200 \mu\text{g disc}^{-1}$ for each and the result was compared with standard antibiotic Nystatin $200 \mu\text{g disc}^{-1}$. The antifungal activity was determined after 72 hours of incubation at room temperature (30°C) and the obtained results are cited in Table 2. It was observed that three compounds i.e. C_1 , C_2 , & C_4 showed more antifungal active than other two compounds C_3 and C_5 .

Minimum Inhibitory Concentration (MIC): The minimum inhibitory concentration (MIC) of the compounds C_1 , C_2 , C_3 , C_4 and C_5 was determined against *Shigella dysenteriae*, *Salmonella typhi*, *Bacillus subtilis* and *Streptococcus β -haemolyticus* by serial dilution technique and the values were shown in the Table 3. The MIC values of the compound C_1 against *Shigella dysenteriae*, *Salmonella typhi*, *Bacillus subtilis* and *Streptococcus β -haemolyticus* were 64, 32, 32 and $64 \mu\text{g ml}^{-1}$ respectively, for compound C_2 64, 32, 16 and $32 \mu\text{g ml}^{-1}$ respectively, for compound C_3 128, 64, 32 and $32 \mu\text{g ml}^{-1}$ respectively, for compound C_4 16, 8, 8 and $4 \mu\text{g ml}^{-1}$ respectively and that for compound C_5 64, 16, 64 and $32 \mu\text{g/ml}$ respectively. From the MIC values, it was found that the compounds C_2 , C_4 and C_5 were more potent against *Bacillus subtilis* and *Salmonella typhi*.

It was concluded that among the tested compounds, the compound C_4 (i.e. $\text{SbCl}_3, \text{C}_6\text{H}_5\text{COCH}_3$) possesses substantial antimicrobial activity with a minimum inhibitory concentration. By comparing the results with previously published results (Biswas *et al.*, 2002) of antibacterial activity of benzene sulfonic acid derivative complex compounds, we can say that our

Table 1: *In vitro* antibacterial activity of the compound C₁, C₂, C₃, C₄, C₅ and Standard Kanamycin

Test organisms	Diameter of zone of inhibition (in mm)						Kanamycin 100 µg disc ⁻¹
	C ₁ 100 µg disc ⁻¹	C ₂ 100 µg disc ⁻¹	C ₃ 100 µg disc ⁻¹	C ₄ 100 µg disc ⁻¹	C ₄ 30 µg disc ⁻¹	C ₅ 100 µg disc ⁻¹	
Gram positive bacteria							
<i>Bacillus subtilis</i>	17	25	19	38	27	40	24
<i>Bacillus megaterius</i>	18	28	18	30	22	28	28
<i>Staphylococcus aureus</i>	8	9	16	35	25	32	22
<i>Streptococcus β haemolyticus</i>	16	24	22	33	26	28	22
<i>Sarcina lutea</i>	19	21	17	34	26	12	23
Gram negative bacteria							
<i>Salmonella typhi</i>	25	18	15	30	25	29	19
<i>Shigella dysenteriae</i>	20	20	21	28	20	28	20
<i>Shigella boydii</i>	21	19	22	26	21	29	24
<i>Shigella sonnei</i>	20	21	18	25	16	24	23
<i>Shigella flexneri</i>	23	24	16	22	15	17	28
<i>Shigella shiga</i>	20	22	22	23	14	30	26
<i>Escherichia coli</i>	23	23	23	26	19	25	20
<i>Klebsiella sp.</i>	18	20	16	30	23	31	21
<i>Pseudomonas aeruginosa</i>	20	18	15	26	20	29	20

Table 2: *In vitro* antifungal activity of the compounds C₁, C₂, C₃, C₄, C₅ and Nystatin

Test fungus	Diameter of zone of inhibition (in mm)					
	C ₁ 200 µg disc ⁻¹	C ₂ 200 µg disc ⁻¹	C ₃ 200 µg disc ⁻¹	C ₄ 00 µg disc ⁻¹	C ₅ 200 µg disc ⁻¹	Nystatin 200 µg disc ⁻¹
Human pathogen						
<i>Epidermophyton floccosum</i>	10	9	10	18	0	22
<i>Aspergillus niger</i>	14	18	15	19	6	30
<i>Candida albicans</i>	20	14	18	13	10	20
Plant pathogen						
<i>Aspergillus flavus</i>	20	15	10	12	8	20
<i>Fusarium species</i>	7	25	7	10	6	15
Tricoderma species	15	20	9	10	8	18
<i>Bipovis species</i>	20	35	10	10	0	16
<i>Mucor species</i>	21	18	15	12	10	30

Table 3: MIC values of the compounds C₁, C₂, C₃, C₄ and C₅, against two Gram positive and two Gram negative bacteria

Test organisms	Minimum inhibitory concentration (µ gm ml ⁻¹)				
	C ₁	C ₂	C ₃	C ₄	C ₅
<i>Shigella dysenteriae</i>	64	64	128	16	64
<i>Salmonella typhi</i>	32	32	64	8	16
<i>Bacillus subtilis</i>	32	16	32	8	64
<i>Staphylococcus β haemolyticus</i>	64	32	32	4	32

tested compounds are more superior for selection of a suitable chemotherapeutic agent. Further, acute toxicity and other pharmacological tests are necessary to utilize the compound C₄ as a potential therapeutic agent.

References

Barry, A.L., 1980. Procedures for testing antimicrobial agents in agar media. In: Antibiotic in Laboratory medicine. (V. Lorian Ed.) Williams Wilkin's Co. Baltimore, USA. pp: 1-23.

Bauer, A.W., W.M.M. Kirby, J.C. Sherris and M. Turck, 1966. Antibiotic susceptibility testing by a standardized single disc method. Am. J. Clin. Pathol. 45: 493- 496.

Biswas, M.H., A. H.M. Zakaria, A. Farroque, C.M. Zakaria, M. Zakir Sultan, G. Sadik and M.S.A. Bhuiyan, 2002. *In vitro* antibacterial and cytotoxic activity of a benzene sulfonic acid derivative complex compounds. Bangladesh Pharm. J., 12: 43-46.

Islam, A., A. Sayeed, M. S. A. Bhuiyan, M. A. Mosaddik, A. M. Khan, M. A. Rashid and M. A. Islam, 2001. *In vitro* antimicrobial effect of three terpenes isolated from the bark of *Z. budrunga*. Pak. J. Bio. Sci., 4: 711- 713.

Pratt, W.B. and W. R. Rudden, 1979. The anticancer drugs, pp: 251-254.

Reiner, R.1982. Detection of antibiotic activity. In. Antibiotics an introduction. Roche Scientific Service, Switzerland, pp: 21-25.

Rios, J.J., M.C. Reico and A. Villar, 1988. Antimicrobial screening of natural products. J. Entho. Pharmacol., 23: 127-149.

Zakaria, C.M., A. Farroque, M.R. Islam and M.H. Biswas, 2000. Antimicrobial screening of ferrocene derivative compounds. Oriental J. Chem., 16: 85-90.